Federal Jury Holds Amgen Inc. Accountable for Antitrust Violations; Awards Regeneron $406.8 Million in Damages

In a significant legal development, a federal jury has found Amgen Inc., based in Thousand Oaks, California, liable for both federal and state antitrust violations. The verdict, delivered after just over half a day’s deliberation, implicates the biopharmaceutical giant on 10 of the 11 claims stated in the complaint. These include monopolization and unreasonable restraint of trade, actions contravening the Sherman Act. The jury awarded $135.6 million in compensatory damages and $271.2 million in punitive damages to the plaintiff, Regeneron Pharmaceuticals Inc., a rival drug company. For further details, visit the National Law Journal.